Alberta COVID-19 Immunization Program Update

October 21, 2021

Co-administration of COVID-19 vaccines and other vaccines

COVID-19 vaccines may now be co-administered with all other vaccines.

Third dose of COVID-19 vaccine for high-risk groups

The following immunocompromising conditions are eligible for a third dose of COVID-19 vaccine at least eight weeks after their second dose:

  • solid organ transplant recipients
  • hematopoietic stem cell transplants recipients
  • malignant hematologic disorders and non-hematologic malignant solid tumors
  • chronic kidney disease on dialysis
  • receipt of chimeric antigen receptor (CAR)-T-cell therapy
  • primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome)
  • advanced untreated HIV infection and those with acquired immunodeficiency syndrome
  • active treatment with the following categories of immunosuppressive therapies: 
    • anti-B cell therapies (monoclonal antibodies targeting CD19, CD20, CD22 and CD52), 
    • high-dose systemic corticosteroids,
    • alkylating agents, 
    • antimetabolites,  
    • tumor-necrosis factor (TNF) inhibitors, or 
    • agents that are significantly immunosuppressive.

Residents of supportive living facilities are eligible for a third dose of COVID-19 vaccine at least 5 months after their second dose has been administered.

Individuals 75 years of age and older and all First Nations, Metis and Inuit adults 65 years of age and older at least 6 months after the second dose.

See Alberta immunization policy for information.

The AMA advances patient-centered, quality care by advocating for and supporting physician leadership and wellness.